Ocrelizumab-induced colitis-critical review and case series from a Romanian cohort of MS patients.

ABSTRACT:

Background

Widespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world observation. Among these, drug-induced colitis is a rare, but severe side effect, prompting a recent FDA statement regarding this safety concern. Objectives: We analyzed a cohort of ocrelizumab treated patients in our MS center to evaluate the incidence of drug-induced colitis.

Methods

We present a critical review of the available literature on diagnosis and management of anti-CD20 induced colitis and display a case series of 3 suspected patients in our cohort.

Results

Two patients met the full criteria for ocrelizumab-induced colitis, while a third partially met the crite

SUBMITTER: Voda IM 

PROVIDER: S-EPMC11835689 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature